Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: Results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy

Revista Iberoamericana de Micologia

Volumn 26, Issue 3, 2009, Pages 194-197

  Arechavala, Alicia Irene ^a   Ochiuzzi, María Eugenia ^a   Borgnia, María Daniela ^a   Santiso, Gabriela María ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

AIDS; Amphotericin B; Cryptococcosis; Fluconazole; MIC; Susceptibility

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCONAZOLE; HIV SEROPOSITIVITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

FILOBASIDIELLA NEOFORMANS;

EID: 67849121814     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.riam.2009.02.001     Document Type: Article

References (26)

1. Alexander B., and Pfaller M. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 43 (2006) S15-S27
2. Arechavala A., Robles A.M., Negroni R., Bianchi M., and Taborda A. Valor de los métodos directos e indirectos de diagnóstico de las micosis sistémicas asociadas al SIDA. Rev Inst Med Trop S Paulo 35 (1993) 163-169
3. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 45 (2007) 569-587
4. Barry A.L., Bille J., Brown S., Ellis D., Meis J., Pfaller M., et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 38 (2000) 3457-3459
5. Bianchi M., Robles A.M., Vitale R., Helou S., Arechavala A., and Negroni R. The usefulness of blood-culture in diagnosing HIV-related systemic mycoses: evaluation of a manual lysis-centrifugation method. Med Mycol 38 (2000) 77-80
6. Borann S., Monchy D., Vann M., Keo C., Sarthou J.L., and Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to march 2002. J Antimicrob Chemother 54 (2004) 563-565
7. Brandt M., Pfaller M., Hayyeh R., Hamill R., Pappas P., Reingold A., et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States : 1992 to 1994, and 1996 to 1998. Antimicrob Agents Chemother 45 (2001) 3065-3069
8. Casadevall A., Spitzer E., Webb D., and Rinaldi M. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent Cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 37 (1993) 1383-1386
9. Chang W.N., Huang C.R., Lei C.B., Lee P.Y., Chien C.C., Chang H.W., et al. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from Southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn J Infect Dis 57 (2004) 113-115
10. Dannaoui E., Abdul M., Arpin M., Michel-Nguyen A., Piens M., Favel A., et al., French Cryptococcosis Study Group. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 50 (2006) 2464-2470
11. Fernandes O.F., Passos X.S., Souza L.K.H., Miranda A.T.B., Cerqueira C.H.P.V., and Silva M.R. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiania, Brazil. Mem Inst Oswaldo Cruz 98 (2003) 839-841
12. Jessup C., Pfaller M., Messer S., Zhang J., Tumberland M., Mbidde E., et al. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbiol 36 (1996) 2874-2876
13. Kwon-Chung K.J., Polacheck I., and Bennett J.E. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 15 (1982) 535-537
14. Lamb D.C., Corran A., Baldwin B.C., Kwon-Chung J., and Ketty S.L. Resistant P450A1 activity in azole antifungal tolerant Crypcotoccus neoformans from AIDS patients. FEBS Lett 368 (1995) 326-330
15. Lozano-Chiu M., Paetznick V., Ghannoum M., and Rex J. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A Methodologies. J Clin Microbiol 36 (1996) 2817-2822
16. Marr K.A., Lyons C.N., Ha K., Rustad T.R., and White T.C. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 45 (2001) 52-59
17. Miller J.L., Schell W.A., Wills E.A., Toffaletti D.L., Boyce M., Benjamin D.K., et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemoter 48 (2004) 384-387
18. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A2. 2nd ed (2002), National Commmittee for Clinical Laboratory Standards, Wayne, PA
19. Negroni R. Micosis asociadas al SIDA. In: Benetucci JA, editor. SIDA y enfermedades asociadas. 2nd ed. Buenos Aires, FUNDAI, 2001. p. 301-24.
20. Paugan A., Dupuy-Camet J., Blanche P., Gaugueux J., Tourte-Schaefer C., and Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 19 (1994) 975
21. Pfaller M., Messer S., Boyken L., Rice C., Tendolkar S., Hollis R., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 43 (2005) 2163-2167
22. Rodero L., Córdoba S., Cahn P., Soria M., Lucarini M., Davel G., et al. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med Mycol 38 (2000) 201-207
23. Salkin I.F., and Hurd N. New Medium for differentiation of Cryptococcus neoformans serotype pairs. J Clin Microbiol 15 (1982) 169-171
24. Sanati H., Messer S., Pfaller M., Witt M., Larsen R., Espinel-Ingroff A., et al. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 34 (1996) 1280-1282
25. Sanglard D. Clinical relevance of mechanism of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 20 (2002) 225-234
26. Yamazumi T., Pfaller M., Messer S., Hoston A., Boyken L., Hollis R., et al. Characterization of heteroresistance to fluconazole among clinical isolates of C neoformans. J Clin Microbiol 41 (2003) 267-272